ALDX Aldeyra Therapeutics

-

Aldeyra Therapeutics Beat Consensus Estimates

Thursday, November 5, 2026 · 12:00 AM ET

Aldeyra Therapeutics (ALDX) reported a loss of $0.06 per share on revenue of $0.00 million for the third quarter ended September 2026. The consensus estimate was a loss of $0.11 per share. The company beat consensus estimates by 45.45%.

Aldeyra Therapeutics Inc is developing a treatment for diseases related to high levels of free aldehydes, naturally occurring pro-inflammatory toxins.

Earnings Whisper Grade —
Power Rating—
Reported Earnings
($0.06)
Earnings Whisper®
—
Consensus Estimate
($0.11)
Earnings Surprise
Earnings Growth53.8 %
Reported Revenue
—
Revenue Estimate
—
Revenue Surprise
Revenue Growth—